Pontecorvo MJ, Joshi AD, Skovronsky DM, Mintun MA.
Florbetapir F 18 and 11C-PIB PET imaging provide concordant measures of underlying brain amyloid pathology.
Human Amyloid Imaging 2011 Meeting Abstracts. 2011 Jan 15;
Background: 11C-PIB was the first and to date most thoroughly studied amyloid imaging agent. Emerging
18F-labeled ligands such as florbetapir will expand availability of PET amyloid imaging. The transition from 11C-PIB
to florbetapir F 18 PET amyloid imaging in the ADNI protocol provides an opportunity to compare performance of
the two ligands.
Methods: Florbetapir F 18 imaging results (qualitative visual read (As+/As-) and cortical to cerebellum SUVR)
were compared to the most recent 11C-PIB imaging results for the first 9 subjects (7 MCI and 2 cognitively normal
controls) with data available for both ligands in the ADNI database. Mean time between the florbetapir-PET scan
and the most recent 11C-PIB scan was 1.5 years.
Results: Qualitative visual reads of the florbetapir F 18 and 11C-PIB scans yielded identical results. The same
3 subjects were rated As+, with the remaining 6 subjects rated As-. The correlation between florbetapir F 18
and 11C-PIB mean cortical to cerebellar SUVR was statistically significant (r = 0.98, p Conclusions: These preliminary results suggest that Florbetapir F 18 and 11C-PIB PET scans provide concordant
estimates of brain amyloid burden. Additional studies, with Florbetapir F 18 and 11C-PIB PET scans conducted in
closer temporal proximity, are required to confirm the limits of concordance between these tracers.
Mean SUVR (Standard Deviation) Cohen's d
Florbetapir F 18 1.64 (0.110) 0.95 (0.077) 7.25
11C PIB 2.06 (0.188) 0.99 (0.070) 7.58